Major players in the iris melanoma treatment market include Novartis AG (Switzerland), Pfizer Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca Plc (U.K.), Sanofi (France), Elekta AB (Sweden), Varian Medical Systems (now part of Siemens Healthineers) (U.S.), Eckert & Ziegler BEBIG (Germany), Castle Biosciences, Inc. (U.S.), and Aura Biosciences (U.S.).
In March 2023, Bristol-Myers Squibb Company introduced an expanded patient access program for its immunotherapy agents specifically for advanced melanoma, including a focus on ocular melanoma patients.
The countries covered in the iris melanoma treatment market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.